Skip to main content
Premium Trial:

Request an Annual Quote

Animal Biotech Shop MetaMorphix Selling Assets

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Animal biotechnology firm MetaMorphix today announced the sale of its assets as part of its Chapter 11 bankruptcy filing.

The sale is for both its businesses, one directed at animal genomics, the other at growth and differentiation factors. American MedTech Advisors is advising the Calverton, MD.-based firm on the sale.

The animal genomics business is operated as a wholly owned subsidiary, MMI Genomics, based in Davis, Calif. It provides DNA testing for the livestock and companion animal markets.

The growth and differentiation business platform was licensed from the Johns Hopkins University. Its lead growth factor is myostatin, a natural regulator of skeletal muscle.

Bids for the assets are being accepted by MetaMorphix until 4 p.m. March 3. An auction will be held on March 8. Final court approval is expected the following day.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.